Category: Sponsors

Wildflower Enters Distribution Agreement

VANCOUVER, British Columbia, March 22, 2018: Wildflower Marijuana Inc. (CSE: SUN) (FWB: RSP) (“Wildflower” or the “Company”) entered into a Procurement and Transfer of Goods Agreement with one of California’s largest distributors through its licensed partner. As part of this agreement, Wildflower has entered into a Marketing Program Agreement to support sales. The structure of this arrangement is in order to comply with California regulations and replaces the previous agreement through which King products were being distributed. The agreement contemplates the future sale of Wildflower branded products as soon as available within the regulated market. With the acquisition of the multiple California licenses announced on March 19, 2018, Wildflower will have the ability to manufacture its products in Los Angeles and sell through one of the largest distributors in California. Wildflower CEO, William MacLean stated, “We are pleased to have navigated the complex California regulatory requirements and finalized our distributor arrangement as this now paves the way for future purchase orders for King and Wildflower products. This distribution, combined with the ability to manufacture, will allow Wildflower to gain further market penetration into the world’s largest regulated cannabis market.” About Wildflower Marijuana Inc. Wildflower is a cannabis company focused on developing and designing branded cannabis products. Wildflower sells its CBD+ products online and to retailers throughout the US and also produces and markets its THC products in regulated cannabis...

Read More

Namaste Announces Non-Binding Term Sheet With Australian-Based Medical Cannabis Company Pharmacann Company Pty Ltd.

Vancouver, British Columbia, Canada – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE: N)(FRANKFURT: M5BQ)(OTCMKTS: NXTTF) is pleased to announce that it has signed a nonbinding Terms Sheet (the “Terms Sheet”) with PharmaCann Pty Ltd. (“PharmaCann”), whereby Namaste will participate in an investment to purchase a 10% equity position in PharmaCann. PharmaCann currently operates with existing licenses to import, export and wholesale medical cannabis issued by the Australian Government Department of Health. Namaste’s investment in PharmaCann will be used by PharmaCann to proceed with its application to further secure a cultivation license. The Australian market represents a major component of Namaste’s current revenue, which is derived in hardware sales, and remains a primary focus of Namaste’s strategic initiatives as it looks to target the Australian medical cannabis industry. Namaste believes PharmaCann’s import, export and wholesale licenses bring immediate value to the Company and believes that PharmaCann has the ability to obtain a cultivation license which will further enhance Namaste’s ability to penetrate global markets. In addition to Namaste’s strategic investment in PharmaCann, the Terms Sheet outlines additional business ventures between both parties as outlined below. Key Terms: • Namaste will provide a cash investment for 10% equity in PharmaCann. • Namaste will purchase 250kg annually of medical cannabis for export to Canada under the Company’s wholly owned subsidiary Cannmart Inc. (“Cannmart”) for the next three-year, subject to approval by...

Read More

Zynerba Pharmaceuticals Announces Poster Presentation at the 2018 Annual Meeting of the American Academy of Neurology (AAN)

Devon, PA, March 22, 2018 — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare neurological and psychiatric disorders with high unmet medical needs, today announced the acceptance and presentation details of a late breaking poster at the 2018 Annual Meeting of the American Academy of Neurology (AAN) in Los Angeles, CA from April 21st through 27th, 2018. The poster has been accepted to the Emerging Science session at the AAN. Wednesday April 25, 2018 Poster title: “Transdermal Cannabidiol (CBD) Gel for the Treatment of Focal Epilepsy in Adults” Session: Emerging Science – poster presentations Poster session: IV Poster number: P4.468 Author presentation time: 5:30PM – 7:30PM EDT Display time: 11:30AM – 7:00PM EDT About Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals (NASDAQ:ZYNE) is a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric diseases with high unmet medical needs. We are dedicated to improving the lives of people with severe health conditions by developing cannabinoid medicines designed to meet the rigorous efficacy and safety standards established by global regulatory agencies. Through the discovery and development of these potentially life-changing medicines, Zynerba seeks to improve the lives of patients battling severe, chronic health conditions including Fragile X syndrome, refractory epilepsies, Tourette Syndrome, and other neuropsychiatric disorders....

Read More

Scythian Biosciences Corp. Announces Expansion of its Global Footprint into Jamaica with Binding Letter of Intent

– Marigold Teams with University of West Indies for Research and Development – – Marigold Receives Five Conditional Cannabis Related Licenses – TORONTO, March 22, 2018 (GLOBE NEWSWIRE) — Scythian Biosciences Corp. (the “Company” or “Scythian”) (TSXV:SCYB) (Frankfurt:9SB) (OTC Pink:SCCYF) is pleased to announce that it has entered into a binding letter of intent dated March 21, 2018 (“Letter of Intent”) to acquire Marigold Acquisitions Inc. (the “Acquisition”). The Acquisition will result in Scythian becoming a major stakeholder of Marigold Projects Jamaica Ltd. (“Marigold”), a Jamaican company, which has received conditional licenses to cultivate, process, sell and provide therapeutic or spa services utilizing cannabis products. In consideration, Scythian will issue 1,500,000 common shares at the current price per share of $23.00 to the selling parties. Following completion of the Acquisition, the Company will own a 49% interest in Marigold as well as a 95% royalty interest in the net revenues from products sold by Marigold. Marigold was granted one of only three original permits in Jamaica by the Ministry of Science and Technology for the research and development (“R&D”) of cannabis products. The experimental R&D permit allows for the immediate cultivation of cannabis. In addition, the University of West Indies and Marigold have signed a strategic agreement to jointly develop and test products derived from high cannabidiol cannabis sativa strains to establish their efficacy in treating diabetes, hypertension, pain...

Read More

Lexaria Bioscience Corp. Receives New U.S. Patent Allowance for “Composition of Matter” Cannabinoid Delivery

Kelowna, British Columbia – March 22, 2018 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, announces it has received a new Notice of Allowance from the United States Patent and Trademark Office (“USPTO”) providing for “composition of matter” claims that protect the specific combination of substances which enable improved taste and bioabsorption properties of its DehydraTECH technology for the delivery of cannabinoids. This is a significant addition to Lexaria’s existing manufacturing “method of use” patent rights previously granted. “This Notice of Allowance applies to the delivery of both psychoactive and non-psychoactive cannabinoids as lipophilic active agents formulated together with the edible fatty acids that enable the powerful bioavailability and taste enhancing properties of the DehydraTECH technology,” said John Docherty, President. “This allowance has been granted by the USPTO upon review of the compelling scientific data Lexaria has amassed demonstrating its significant bioavailability performance enhancement properties.” Under USPTO practice, there is no opposition period between allowance and issuance. The patent application number is 15/225,802, “Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof”. As has been Lexaria’s experience in the past, the Company expects the formal granting of the new patent within roughly one hundred days or less. Lexaria has additional patent applications that remain within the USPTO process, of both the composition of matter and...

Read More

Kalytera Announces Next Issuance of Shares under Services Agreement with Salzman Group

SAN FRANCISCO and TEL AVIV, Israel, March 22, 2018 (GLOBE NEWSWIRE) — Kalytera Therapeutics, Inc. (TSX VENTURE:KALY) (OTCQB:KALTF) (the “Company” or “Kalytera”) today announced that the Company has elected to issue 444,943 common shares of the Company (“Common Shares”) to The Salzman Group in payment of the most recent invoice issued under the services agreement with The Salzman Group previously announced on December 7, 2017 (the “Agreement”). Under the Agreement, The Salzman Group provides, among other services, clinical study management services in relation to the Phase 2 study evaluating the use of cannabidiol in the prevention of graft versus host disease. The invoice owing to The Salzman Group is in the amount of US$112,798 (or C$146,163.65 based on the daily average exchange rate for March 21, 2018 published by the Bank of Canada). The number of Common Shares to be issued is based on a deemed issue price of C$0.3285 per Common Share, being 90% of the closing price of the Common Shares on the TSXV on March 21, 2018, the trading day prior to the Company’s election to pay the invoice in Common Shares. The Common Shares are expected to be issued to The Salzman Group on or about March 27, 2018. About Kalytera Therapeutics Kalytera Therapeutics, Inc. (“Kalytera”) is pioneering the development of a next generation of cannabinoid therapeutics. Through its proven leadership, drug development expertise, and...

Read More